CSHP - California Society of Health-System Pharmacists

02/07/2026

West Coast Health Alliance Endorses Annual Update of American Academy of Pediatrics Vaccine Schedule

The West Coast Health Alliance (WCHA), which consists of state health officials from California, Oregon, Hawaii, and Washington, and the California Department of Public Health (CDPH), released a statement endorsing the 2026 American Academy of Pediatrics (AAP) Recommended Child and Adolescent Immunization Schedule. The 2026 AAP Recommended Child and Adolescent Immunization Schedule differs from the recent national changes made by the Centers for Disease Control (CDC).

Pursuant to Health and Safety Code section 120164, the CDPH will continue to adopt the most recent AAP immunization recommendations for California. The 2026 AAP Immunization recommendations are similar to the previous recommendations issued by AAP. These recommendations were adopted by the CDPH and endorsed by the West Coast Health Alliance. For the mpox vaccine, the CDPH has also issued separate recommendations to increase access for that vaccine to adolescents at increased risk of infection.

Health insurance coverage in California will continue to cover the vaccines recommended in the 2026 AAP recommendations, as it is unchanged from prior CDPH recommendations. Parents with any questions about the effectiveness and safety of vaccines should discuss with their healthcare provider, such as pharmacists, their concerns.

View the full statement here:
https://www.cdph.ca.gov/Programs/OPA/Pages/NR26-006.aspx

View the 2026 American Academy of Pediatrics (AAP) Recommended Child and Adolescent Immunization Schedule here:
https://downloads.aap.org/AAP/PDF/AAP-Immunization-Schedule.pdf

02/06/2026

🚨 Important Update for Medi-Cal Rx Providers

Starting in mid-2026, ICD-10 diagnosis codes will be required for all pharmacy claims. To help facilitate a smooth transition, we need to hear from you!

Take our brief survey ➡️ https://bit.ly/4bE3svH

02/06/2026

CSHP is proud to host a special webinar on Assembly Bill 1503: Removing Barriers and Improving Patient Safety.

We are honored to welcome Anne Sodergren (Executive Officer, CA Board of Pharmacy) to discuss the transition to a standard of care model and how recent legislative changes will reshape your practice.

Why tune in? ✅ Understand the impact of AB 1503. ✅ Get a firsthand look at Board of Pharmacy updates. ✅ Earn 1.0 hour of CE credit!

🗓 When: Thursday, March 12, 2026 ⏰ Time: 6:30 PM PT 👥 Audience: Pharmacists & Technicians

Register ➡️ https://bit.ly/4tdpAmS

02/05/2026

Free CE from Medscape and MMWR: Intimate Partner Violence and Pregnancy and Infant Health Outcomes—Pregnancy Risk Assessment Monitoring System, Nine US Jurisdictions, 2016-2022

Medscape will be hosting a free online CE activity to discuss new research highlighting the multiple negative outcomes associated with experiencing intimate partner violence (IPV) during pregnancy.

Upon completing this activity, participants will be able to assess how intimate partner violence during pregnancy can affect pregnancy and infant health outcomes, recognize the importance of IPV screening and strategies for the primary prevention of IPV, distinguish the most common type of IPV during pregnancy experienced by women with a recent live birth, and analyze the effect of IPV on pregnancy and infant health outcomes.

Pharmacists are a part of the target audience for this activity.

Valid for credit through 12/23/2026.
Registration is not required.
This event offers 0.25 contact hours in pharmacy education.

View the Medscape Activity information here:
https://www.medscape.org/viewarticle/1002929

02/05/2026

Beyond the Credits: Why PCPSC 2026 is a Must-Attend ✨

We know you need CE, but why not gain tools that actually transform your daily practice? Join us in Monterey this February to dive deep into the protocols that save lives.

What’s on the agenda? ✅ Culture: Building safety into every pharmacy workflow. ✅ Protocols: Evidence-based strategies to reduce medication errors. ✅ Compliance: Navigating the latest Board of Pharmacy regulations.

Invest in your profession. Invest in your patients. 🤝

Register ➡️ https://bit.ly/3KyAceO

02/03/2026

California Becomes First State to Join WHO-Coordinated International Network

Governor Gavin Newsom announced California will become the first state to join the World Health Organization (WHO)’s Global Outbreak Alert & Response Network (GOARN). GOARN is a WHO-coordinated international network that brings together hundreds of public health institutions, national governments, academic centers, laboratories, and response organizations worldwide. Currently, California is the only state to join the WHO’s GOARN.

This partnership is a response to the Trump administration withdrawing the United States from the WHO, citing COVID-19 failures, politicization, and a shift to bilateral health efforts. California will not be affected by this decision as a collaborator in the WHO’s GOARN. California will continue to remain at the forefront of public health preparedness and respond to emerging public health threats.

View the Governor's news announcement here:
https://www.gov.ca.gov/2026/01/23/governor-newsom-meets-with-world-health-organization-director-general-announces-california-becomes-first-state-to-join-who-coordinated-international-network/

02/02/2026

New Compounding Regs? We’ve Got Your Back! 🛡️

CSHP is creating a "Compounding Implementation Guide" to help our members stay ahead of the latest CA Board of Pharmacy changes. But first, we need your input!

Tell us what resources, tools, and templates would make your life easier. Help us build a toolkit that works for you.

⏳ Don’t wait—the survey closes on February 22nd!

Take the survey ➡️ https://bit.ly/3ZkvbKy

02/02/2026

Collaboration and community are at the heart of what we do! 🤝

We were honored to have CSHP leaders join our partners at the Association of Black Health-System Pharmacists (ABHP) Luncheon. It was an incredible afternoon of connection and shared commitment to the future of pharmacy practice.

We are proud to stand alongside ABHP as we continue to advocate for our profession and the diverse communities we serve.

02/01/2026

Meet Timofey Shimko, PharmD, CPPS! ✨ 🏛️

Timofey’s CSHP story started with a single suggestion from a supervisor to attend Legislative Day. That one spark of curiosity led him to the Government Affairs Advisory Committee, the New Practitioner Executive Committee, and now, a seat on the CSHP Board of Directors!

"CSHP brings together pharmacists across generations and practice settings, and I see that diversity as one of our greatest strengths."

Timofey is passionate about:
✅ Strengthening mentorship for new practitioners.
✅ Making advocacy practical and relevant.
✅ Bridging the gap between student life and professional practice.

Join us in celebrating Timofey’s leadership and his commitment to the !

Read the full spotlight: https://bit.ly/49T7ptR

01/31/2026

CDC HAN: New World Screwworm Outbreak Moves into Northern Mexico

The Centers for Disease Control and Prevention (CDC) has issued a Health Alert Network (HAN) Health Advisory regarding information about recent New World screwworm (NWS) animal cases in the Mexican state of Tamaulipas, which shares a border with the U.S. state of Texas. NWS is a parasitic fly that primarily affects livestock but can be a concern for pets, wildlife, and humans. Cases of NWS in people can be fatal if left untreated. No NWS infestations related to this outbreak have been identified in people or animals in the United States as of January 20, 2026.

The CDC recommends that healthcare professionals consider NWS in people who present with visible larvae or egg masses in a wound, ears, eyes, nose, mouth, or other body or***ce, destruction of healthy tissue, sensation of movement, foul odor, bloody discharge, swelling, and pain, and reports recent travel to regions where NWS is present. In places where NWS is present, healthcare professionals should advise patients to follow recommended precautions, such as cleaning and covering all wounds, no matter how small or the location on the body or wearing clothing that is loose-fitting and limits skin exposure, such as long-sleeved shirts and pants, socks, and hats.

Healthcare professionals with patients with suspected NWS larval infestations should consult with health departments and the CDC and collect and submit larvae from patients to the CDC for clinical diagnosis and confirmation. Treatment for patients with suspected NWS larval infestations is thorough removal of all larvae from the affected site by killing all larvae and eggs. Failure to kill and properly dispose of all larvae or eggs could result in the new introduction and spread of NWS in the local environment. Healthcare professionals should reexamine treated lesions after 24–48 hours to confirm no live larvae remain.

Healthcare professionals are recommended to immediately report all suspected human cases to the state, tribal, local, or territorial health department, and work with your health department to seek a confirmatory diagnosis with CDC’s Diagnostic Parasitology Lab (DPDx).

View the CDC’s HAN Health Advisory here:

HAN Health Advisory: New World Screwworm: Outbreak Moves into Northern Mexico

01/30/2026

Registration is officially OPEN for CSHP’s 2026 Pharmacy Policy & Legislative Day! Join us in Sacramento as we take the lead on the legislation that shapes our profession.

Why you need to be there:

🗣️ Raise Your Voice: Advocate directly for your patients and your profession.

🏛️ Meet the Lawmakers: Take your seat at the table with California Legislators and their staff.

📈 Stay Informed: Get the inside scoop on key bills.

🤝 Network: Connect with colleagues and healthcare leaders at the Capitol.

🗓 Date: April 7, 2026
📍 Location: California Chamber of Commerce, Sacramento, CA
🎟 Registration: Pharmacists ($80) | Students & Techs ($40)

Register today ➡️ https://www.cshp.org/PPLD-2026

01/29/2026

FDA Approves New Treatment to Prevent Vomiting Induced by Motion

The U.S. Food and Drug Administration (FDA) has approved a new treatment for adults to prevent vomiting induced by motion. Tradipitant (Nereus) is a substance P/neurokinin-1 (NK-1) receptor antagonist administered as an oral capsule.

The safety and efficacy of tradipitant (Nereus) were evaluated in two randomized, double-blind, placebo-controlled trials, Study 1 and Study 2, with adult subjects with a history of motion sickness receiving either a single 85 mg or 170 mg dose of tradipitant (Nereus). Additional safety data for the 170 mg dose of tradipitant (Nereus) were obtained from a randomized, double-blind, placebo-controlled trial, Study 3 (NCT03772340).

Warning and precautions for tradipitant (Nereus) include the potential to impair mental and/or physical abilities required for driving a motor vehicle or operating heavy machinery. Patients are warned against driving and other activities requiring complete mental alertness if concomitant use is unavoidable. The most common adverse reactions (incidence ≥5%) for tradipitant (Nereus) are somnolence, headache, and fatigue.

View the FDA’s announcement here:
https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2025

View tradipitant (Nereus) package insert here:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/220152Orig1s000lbl.pdf